Risk Modification Calculator

Lipoprotein(a) Risk Multiplier Calculator

Estimate the approximate relative-risk contribution of Lp(a) to a previously calculated 10-year PREVENT-ASCVD risk.

The 2026 ACC/AHA dyslipidemia guideline identifies progressively higher cardiovascular risk across increasing Lp(a) concentrations. This tool places your laboratory value on that continuum and shows what the associated relative risk could mean in the context of your baseline cardiovascular risk.

Based on 2026 ACC/AHA dyslipidemia guideline reference points

Educational use only. This tool and its outputs do not constitute medical advice, diagnosis, or treatment and do not replace clinical judgment. Independently verify the inputs, equations, assumptions, units, and outputs, and confirm that the tool is appropriate for your intended use before relying on a result.

Bring your baseline risk

This tool needs the 10-year ASCVD result from a validated PREVENT calculator.

Baseline 10-Year PREVENT-ASCVD Risk (%)

Enter the 10-year PREVENT-ASCVD risk calculated using a validated PREVENT risk estimator. This calculator does not independently calculate baseline cardiovascular risk.

Calculate my PREVENT risk on MDCalc

On MDCalc, use the 10-year ASCVD risk result. Return here and enter that percentage above.

Why PREVENT?

The 2026 ACC/AHA dyslipidemia guideline recommends PREVENT-ASCVD instead of the older Pooled Cohort Equations for primary-prevention risk assessment in appropriate adults. PREVENT is intended for primary prevention and should not be used to generate a primary-prevention estimate for someone with established ASCVD.

Enter the laboratory value

Use the Lp(a) concentration and unit reported directly by your laboratory.

Lipoprotein(a), Lp(a)

Unit reported by your laboratory

nmol/L is preferred when available. This calculator does not convert between units using a universal fixed factor.

Result

Two numbers, placed in context.

Enter your validated baseline risk and the Lp(a) result exactly as your laboratory reported it. The result will show the guideline-associated relative-risk reference and a clearly labeled mathematical illustration.

Baseline risk×Lp(a) reference=Illustration

No health values are stored or sent to a database to perform this calculation.

Guideline model

Guideline Lp(a) Risk Reference Points

Approximate relative-risk reference points from the 2026 ACC/AHA multisociety dyslipidemia guideline.

These values are intended as a general guide. Lp(a)-associated cardiovascular risk is continuous, and the reference points should not be interpreted as sharp biological thresholds.

Approx. Lp(a)	Approx. relative risk	Interpretation
30 mg/dL / 75 nmol/L	≈1.2×	Modestly increased relative risk
50 mg/dL / 125 nmol/L	≈1.4×	Guideline risk-enhancing level
100 mg/dL / 250 nmol/L	≈2×	Approximately doubled relative risk
150 mg/dL / 350 nmol/L	≈3×	Approximately three-fold relative risk
180 mg/dL / 430 nmol/L	≈4×	Highest reference point modeled

The mg/dL and nmol/L concentrations shown together are paired guideline reference points. They are not exact biochemical conversions. The calculator uses the laboratory-reported unit and does not convert using a fixed universal factor.

Relative risk meets absolute risk

Why the Same Lp(a) Can Mean Different Things for Different People

Relative risk and absolute risk are not the same thing. A large relative increase may translate into a relatively small absolute change when baseline cardiovascular risk is very low. The same relative increase can matter much more when baseline risk is already elevated.

2% baseline× 2≈4%

8% baseline× 2≈16%

Mathematical illustrations only—not validated PREVENT recalculations.

What Does Your Lp(a) Result Mean?

Lipoprotein(a), or Lp(a), is a largely genetically determined atherogenic lipoprotein and a causal risk factor for atherosclerotic cardiovascular disease. Higher concentrations are also associated with calcific aortic valve stenosis.

Lp(a) is relatively stable across adulthood and only modestly affected by lifestyle. The 2026 guideline recommends measuring it at least once in adulthood to identify inherited Lp(a) burden that may increase cardiovascular risk.

Risk is continuous. The guideline identifies approximately 50 mg/dL or 125 nmol/L and above as a risk-enhancing level and provides broader relative-risk reference points. MendelMD interpolates in log-relative-risk space between those points to visualize where a laboratory result falls. That interpolation is educational and was not itself published or validated by ACC/AHA.

What Happens If Lp(a) Is Elevated?

Elevated Lp(a) is a reason to pay closer attention to the overall burden of modifiable cardiovascular risk. Because Lp(a) is largely genetically determined, current management focuses heavily on factors that can be changed.

LDL-C, non-HDL-C, and apoB
Blood pressure and glycemic health
Smoking or nicotine exposure
Physical activity and dietary pattern
Family history and established ASCVD
Coronary artery calcium when appropriate

The calculator does not prescribe therapy. Use the result as a starting point for a prevention discussion with a clinician.

Important Limitations

This tool does not calculate baseline cardiovascular risk. Use an appropriate validated estimator; PREVENT-ASCVD is the preferred primary-prevention estimator for appropriate adults under the 2026 guideline.
The multiplier is an approximate interpretation of guideline reference points, not a validated individual prediction equation.
The illustrative percentage directly applies a population-level relative-risk estimate to a supplied absolute-risk percentage. That is not equivalent to recalculating risk in a validated survival model.
Lp(a) is not currently an input in PREVENT, and the illustration must not be interpreted as an adjusted PREVENT score.
Risk is continuous. Categories are reference points rather than rigid biological thresholds.
No fixed mg/dL-to-nmol/L conversion is used because apo(a) isoform size and assay characteristics affect the relationship.
Values above 180 mg/dL or 430 nmol/L are not extrapolated beyond the highest modeled reference point.
PREVENT is intended for primary prevention, not for people with established cardiovascular disease.
Do not use this calculator as the sole basis for medication, antithrombotic therapy, diagnostic testing, or other clinical decisions.

Common questions

Lp(a) Risk Calculator FAQ

What Lp(a) level is considered high?

The 2026 ACC/AHA dyslipidemia guideline identifies approximately 50 mg/dL or 125 nmol/L and above as a risk-enhancing level. Risk is continuous, so this is a clinical reference point rather than a sharp biological boundary.

Is 100 mg/dL Lp(a) very high?

Yes. In the guideline reference table, approximately 100 mg/dL corresponds to about a two-fold ASCVD relative-risk estimate compared with the population median reference level.

Is 250 nmol/L Lp(a) high?

Yes. Approximately 250 nmol/L is the paired guideline reference point associated with about two-fold relative ASCVD risk compared with the population median.

Can I convert Lp(a) from mg/dL to nmol/L?

A universal fixed conversion is inappropriate because apo(a) particle size and assay characteristics vary. Use the unit reported by your laboratory. This calculator maintains separate mg/dL and nmol/L scales and never converts between them.

Does PREVENT include Lp(a)?

No. PREVENT does not directly include Lp(a). This calculator is a separate educational risk-modification layer and does not produce a recalculated or validated PREVENT score.

References

Blumenthal RS, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026;153:e1154–e1276. doi:10.1161/CIR.0000000000001423.
Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 2022;43(39):3925–3946.
Patel AP, Wang M, Pirruccello JP, et al. Lp(a) Concentrations and Incident Atherosclerotic Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2021;41(1):465–474. doi:10.1161/ATVBAHA.120.315291.